Enzon Stock Hits New 52-Week Low (ENZN)

NEW YORK ( TheStreet) -- Enzon Pharmaceuticals (Nasdaq: ENZN) hit a new 52-week low Thursday as it is currently trading at $7.38, below its previous 52-week low of $7.42 with 129,976 shares traded as of two p.m. ET. Average volume has been 377,600 shares over the past 30 days.

Enzon has a market cap of $384.6 million and is part of the health care sector and drugs industry. Shares are down 36.7% year to date as of the close of trading on Wednesday.

Enzon Pharmaceuticals, Inc., a biotechnology company, engages in the research and development of therapeutics for cancer patients with unmet medical needs.
  • Practice your ENZN trading strategies and win cash in our stock game.

TheStreet Ratings rates Enzon as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and generally disappointing historical performance in the stock itself. You can view the full Enzon Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%